EE504 Cost-Utility Analysis Comparing Direct Oral Anticoagulant (DOAC) and Low-Molecular-Weight Heparin (LMWH) Therapies for Cancer-Associated Thrombosis (CAT) Treatment in the United States
Abstract
Authors
YE Shin M Hwang ML Mackey A Kumar WK Wu